Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-07

FDA Approved: ABACAVIR AND LAMIVUDINE — Supplemental Application (Cipla USA Inc.)

View source ↗

Summary

FDA approved a supplemental application for the abacavir and lamivudine fixed-dose combination from Cipla USA Inc., updating its labeling for this antiretrovira…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ABACAVIR AND LAMIVUDINE (abacavir/lamivudine)

Snippet

SUPPL AP for ABACAVIR AND LAMIVUDINE (ABACAVIR AND LAMIVUDINE)